Mr. Behr has more than 23 years of experience as an investor and entrepreneur. He has founded several high technology companies, including IN USA, Compact Instruments (acquired by MKS) and Arradiance, and he invested in early-stage ventures at Allied Minds, Inc. and at Seed Partners. Behr was also part of Harvard University's Office of Technology Development, where he launched seven companies and drove numerous technology transfer and commercialization initiatives.
Dr. Bronstein's life sciences career has spanned more than 22 years as an executive, entrepreneur and investor. He co-founded and helped manage several life sciences companies, including Peptimmune (acquired by Genzyme) and Vidus Ocular (acquired by OPKO Health). Most recently, he was CEO of Neuron Systems. Earlier, he was Vice President, Medical Affairs at BioSurface Technology, which went public and was later acquired by Genzyme. He was also a Managing Director at Zero Stage Capital, focused on life sciences investing. Bronstein began his career at the Massachusetts General Hospital and on the faculty at Harvard Medical School.
Access BridgeGap Ventures, based in Cambridge, MA, is actively seeking opportunities in human therapeutics: pharmaceuticals, biopharmaceuticals and therapeutic devices. Advisors to Access BridgeGap include William Koster, PhD, former Senior Vice President for worldwide drug discovery research and early clinical development at Bristol Myers Squibb, and former President and CEO of Neurogen; Manuel Navia, PhD., former Vice Pres
|SOURCE Access Industries|
Copyright©2010 PR Newswire.
All rights reserved